Where Can I Buy NAD+ 500mg?
September 9, 2026
Researchers looking for NAD+ 500mg for laboratory research can purchase it from Neuro Peptides. NAD+,
Retatrutide has gained significant attention owing to its distinctive way of action. Drugs like semaglutide work through the GLP-1 receptor pathway only. However, retatrutide works on all three metabolic receptors at once – GLP-1, GIP, and glucagon. This gives it a broader pharmacological profile than a GLP-1-only drug. Coskun et al. described LY3437943, the compound now known as retatrutide, as a triple agonist with activity at the glucagon, GIP, and GLP-1 receptors.
The difference is important, but it should not be reduced to the idea that “more receptors automatically mean better treatment.” Retatrutide is still investigational, and its clinical results need to be evaluated separately from its proposed mechanism. What makes it different is the way its three receptor activities are combined in one molecule.
The GLP-1 receptor agonists are molecules that mimic the function of the natural hormone glucagon-like peptide-1. Some of the physiological processes regulated by them are insulin secretion dependent on glucose levels, decreased secretion of glucagon if glucose levels are high, delayed gastric emptying, and decreased appetite. Moiz et al. provided an overview of the mechanisms responsible for weight loss caused by GLP-1 receptor agonists, including the role of appetite regulation and metabolism.
Semaglutide is one such compound. In the STEP 1 trial, Wilding et al. found that once-weekly semaglutide 2.4 mg produced substantial weight loss in adults with overweight or obesity over 68 weeks. This provides an important benchmark for understanding what a GLP-1 receptor agonist can achieve on its own.
So, the key point is simple: a GLP-1 receptor agonist is built around one primary receptor pathway. Retatrutide is not.
Retatrutide combines three types of receptor activity in a single peptide.
The first is GLP-1 receptor agonism. This component contributes to appetite regulation, glucose control, and gastrointestinal effects such as delayed gastric emptying. The second is GIP receptor agonism. GIP is another incretin hormone that influences insulin secretion and has effects on adipose tissue and nutrient metabolism. The third is glucagon receptor agonism, which gives retatrutide its most distinctive feature compared with GLP-1-only therapies.
Coskun et al. reported that LY3437943 showed activity at all three receptors and that its pharmacology was designed to combine GLP-1 and GIP incretin effects with glucagon receptor activity. In preclinical models, the authors linked glucagon receptor activation with increased energy expenditure while GLP-1 and GIP receptor activity contributed to reduced calorie intake and metabolic effects.
This does not mean every effect can be assigned to only one receptor. The pathways interact. That interaction is part of what researchers are investigating.
GIP is important because retatrutide is not simply a stronger GLP-1 receptor agonist. It adds another incretin pathway.
GIP normally contributes to glucose-dependent insulin secretion after meals and is also involved in nutrient and metabolic signaling. However, the precise contribution of GIP receptor activation to weight loss remains an active area of research.
This distinction can also be seen when comparing retatrutide with tirzepatide. Tirzepatide activates GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity to those two pathways. In the SURMOUNT-1 trial, Jastreboff et al. demonstrated substantial weight loss with tirzepatide, showing the clinical potential of dual incretin receptor agonism.
Retatrutide therefore represents a further expansion of the multi-receptor approach rather than simply another GLP-1 drug.
The most important distinction is the addition of glucagon receptor agonism.
The conventional GLP-1 receptor agonists lack direct activation of the glucagon receptor. However, retatrutide activates the glucagon receptor directly. This is significant as glucagon is responsible for playing an important role in energy regulation. Glucagon could have some physiological effects such as hepatic glucose production and energy expenditure.
According to the preclinical study done by Coskun et al., the glucagon receptor signaling pathway enhances energy expenditure, whereas activation of all three receptors results in greater weight loss in obese mice than incretin receptors only.
This explains why retatrutide should be studied as a triple agonist. Nevertheless, it is important to draw a line between mechanistic evidence and clinical evidence. Findings from animal and pharmacological studies help explain how retatrutide might work. They do not by themselves establish that the same magnitude of effect occurs in humans.
Semaglutide and retatrutide are different at the receptor level. It was proven that the medication has the potential to reduce body weight and improve metabolism in certain patients. Wilding et al. found that there is a body-weight loss of approximately 15% when using semaglutide 2.4 mg during 68 weeks in the STEP 1 trial.
In turn, retatrutide activates GLP-1, GIP, and glucagon receptors. In their Phase 2 obesity trial, Jastreboff et al. found that patients who received retatrutide experienced dose-dependent body weight loss, and those who received 12 mg of the drug managed to achieve a 24.2% loss of body weight in 48 weeks.
Nevertheless, these figures are worth considering, but they cannot be considered a direct comparison of these medications. Semaglutide and retatrutide were used in different clinical trials that had different designs and different patients.
Tirzepatide provides an even closer comparison because it is also a multi-receptor agonist.
Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide activates those same two receptors while adding the glucagon receptor. That makes the receptor profile the clearest distinction between the two compounds.
In the Phase 3 SURMOUNT-1 trial, Jastreboff et al. reported substantial weight loss with tirzepatide over 72 weeks, demonstrating the effectiveness of dual GIP/GLP-1 receptor agonism. Retatrutide goes one step further pharmacologically by adding glucagon receptor activity.
The important scientific question is whether this third pathway provides meaningful additional benefits without creating unacceptable tolerability or safety issues. That question is being addressed through ongoing clinical development.
No. Calling retatrutide a “stronger GLP-1” misses its main pharmacological difference.
It is more accurate to describe retatrutide as a triple-hormone-receptor agonist. Its GLP-1 activity is only one part of its mechanism. GIP and glucagon receptor activation are also integral to its design. Coskun et al. characterized retatrutide as a triple agonist acting on all three receptor pathways.
This distinction matters when discussing clinical research. A higher weight-loss percentage does not automatically tell us which receptor is responsible for each effect. The three pathways can interact, and researchers are still working to understand how their combined activation translates into long-term clinical outcomes.
The simplest way to understand the difference is to look at the receptor targets:
| Compound | GLP-1 receptor | GIP receptor | Glucagon receptor |
| Semaglutide | ✓ | — | — |
| Tirzepatide | ✓ | ✓ | — |
| Retatrutide | ✓ | ✓ | ✓ |
This progression explains why retatrutide has generated so much interest. It does not rely solely on GLP-1 signaling. It combines GLP-1 and GIP activity with glucagon receptor activation, creating a triple-receptor approach that distinguishes it from both GLP-1-only and dual GLP-1/GIP therapies. Coskun et al. described this three-receptor activity as a defining feature of retatrutide.
Retatrutide differs from other GLP-1 receptor agonists in that its mode of action goes beyond that of the GLP-1 receptor since it targets three receptors instead of one.
The scientific rationale is backed by pharmacological studies by Coskun et al. and clinically proven to be effective in human studies done by Jastreboff et al. and Rosenstock et al.
However, retatrutide should not be described as a proven replacement for existing GLP-1 therapies. It remains an investigational drug. Its long-term safety, durability of weight loss, and clinical role require continued study.
Yes; it should, however, be noted that it would be more precise to call retatrutide a triple receptor agonist, as it works not just with the GLP-1 receptor but with the GIP and glucagon receptor as well. Indeed, according to Coskun et al., LY3437943 was identified as a triple glucagon, GIP, and GLP-1 receptor agonist.
Semaglutide is a GLP-1 receptor agonist, while retatrutide is a GLP-1, GIP, and glucagon receptor agonist.
No. Both activate GLP-1 and GIP receptors, but retatrutide also activates the glucagon receptor. Tirzepatide is therefore a dual agonist, while retatrutide is a triple agonist.
Retatrutide has proven effective in causing weight loss in clinical studies, as demonstrated by the 24.2% mean weight loss at week 48 on 12 mg retatrutide in the Phase 2 study conducted by Jastreboff et al. Nonetheless, a direct comparison clinical study should be carried out to establish whether retatrutide outperforms individual GLP-1 receptor agonists.
No. Retatrutide remains an investigational compound. Its clinical development is ongoing, so research findings should not be treated as evidence that the investigational product is an approved treatment.
What makes Retatrutide distinct from other GLP-1 receptor agonists is the use of the multi-receptor approach. Retatrutide does not involve GLP-1 activation but involves the activation of GLP-1, GIP, and glucagon receptors.
The inclusion of the GIP receptor makes the incretin part more elaborate, while glucagon receptor action introduces an additional path in energy metabolism. The pharmacological basis of this multi-agonist approach was presented by Coskun et al., while Phase 2 clinical research by Jastreboff et al. demonstrated substantial effects on body weight.
The important point about Retatrutide is that it is not a simple GLP-1 receptor agonist. Retatrutide is a novel multi-receptor agent used in metabolism studies. However, promising findings must be regarded with caution since the drug is still investigational.
Researchers looking for NAD+ 500mg for laboratory research can purchase it from Neuro Peptides. NAD+,
Mitochondria have long been understood as essential sites of cell energy production; however, accumulating evidence
Researchers looking for Retatrutide 10mg for laboratory research can find this research compound at NeuroPeptides.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) that has attracted growing interest in research on
MOTS-C is a mitochondrial-derived peptide (MDP) that has been extensively investigated in the context of
MOTS-C is one of the latest mitochondrial-derived research peptides being investigated with growing interest in